Publication | Open Access

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

Phase 1/2Lymphoid NeoplasiaOncologyRefractory Hodgkin LymphomaClinical TrialsPathologyImmune Checkpoint InhibitorCancer TreatmentImmunotherapyMedicineRadiation OncologyPhase 1Health Sciences